Statement on the Passing of John W. Walsh, Founder of the Alpha-1 and COPD Foundations

Washington, DC (March 8, 2017) - The National Health Council released a statement on the Passing of John W. Walsh, Founder of the Alpha-1 and COPD Foundations.

The following statement is from NHC’s Chief Executive Officer, Marc Boutin:

"As many of you are aware, John W. Walsh passed away on March 7, 2017 surrounded by his loving family. John was an absolute legend in the field of patient advocacy. He founded both the Alpha-1 and COPD Foundations, non-profits dedicated to finding a cure for both the genetic form of chronic obstructive disease (Alpha-1 Antitrypsin Deficiency) and for chronic obstructive pulmonary disease (COPD), the third leading cause of death in the United States. Despite leading relatively small organizations, John and his staff have always used their passion and commitment to drive impactful results in a variety of areas ranging from education, to patient services, and public policy. He was never shy to take the most complex issues head on. As a former Board member of the National Health Council, John not only served as a champion for those with Alpha-1 and COPD, but for all people with chronic conditions. Above all, John was one of the warmest, kindest men I ever knew. I am saddened by his passing but feel blessed to have been able to call him a colleague, a mentor, and a friend."
Founded in 1920, the NHC is the only organization that brings together all segments of the health community to provide a united voice for the more than 133 million people with chronic diseases and disabilities and their family caregivers. Made up of more than 100 national health-related organizations and businesses, the NHC's core membership includes the nation’s leading patient advocacy organizations, which control its governance and policy-making process. Other members include professional and membership associations, nonprofit organizations with an interest in health, and representatives from the pharmaceutical, generic drug, insurance, medical device, and biotechnology industries.